# Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo

> **NCT06831734** · — · ENROLLING_BY_INVITATION · sponsor: **Novo Nordisk A/S** · enrollment: 30 (estimated)

## Conditions studied

- Haemophilia A, Haemophilia B

## Interventions

- **DRUG:** Concizumab

## Key facts

- **NCT ID:** NCT06831734
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-05-02
- **Primary completion:** 2031-01-31
- **Final completion:** 2031-01-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06831734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06831734, "Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06831734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*